During the past decade, Instituto de Neurologia de Curitiba conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 2 clinical trials were completed, i.e. on average, 11.8% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 1 clinical trials were completed. i.e. 12.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto de Neurologia de Curitiba" #1 sponsor was "Hoffmann-La Roche" with 12 trials, followed by "Baxalta now part of Shire" with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored, "Bial - Portela C S.A." with 1 trials sponsored and "Cardiovascular Research Center, Brazil" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto de Neurologia de Curitiba" #1 collaborator was "Takeda Development Center Americas, Inc." with 2 trials as a collaborator, "PPD" with 1 trials as a collaborator, "Sunovion" with 1 trials as a collaborator and "Teva Pharmaceuticals USA" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Instituto de Neurologia de Curitiba" are "Multiple Sclerosis" (5 trials), "Alzheimer Disease" (2 trials), "Chronic Inflammatory Demyelinating Polyradiculoneuropathy" (2 trials), "Alzheimer's Disease" (1 trials) and "Arterial Coronary Disease" (1 trials). Many other conditions were trialed in "Instituto de Neurologia de Curitiba" in a lesser frequency.

Most popular intervention types in "Instituto de Neurologia de Curitiba" are "Drug" (15 trials), "Biological" (2 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ocrelizumab" (8 trials), "Placebo" (6 trials), "Antihistamine" (2 trials), "Fenebrutinib" (2 trials) and "Gantenerumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Instituto de Neurologia de Curitiba" are 19 trials for "All" genders.

Currently, there are NaN active trials in "Instituto de Neurologia de Curitiba". undefined are not yet recruiting, 8 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Instituto de Neurologia de Curitiba, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto de Neurologia de Curitiba, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".